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Abstract: Amino acids can modulate cell metabolism and control cell fate by regulating cell survival and cell 
death. The molecular mechanisms involved are mediated by the mTOR complexes mTORC1 and mTORC2 
activity. These complexes are finely regulated and the continuous advancement of the knowledge on their 
composition and function is revealing that their balance may represent the condition that determines the cell fate. 
This is important for normal healthy cells but it is becoming clear, and it is even more important, that the balance 
of the mTORCs activity may also condition the cell fate of cancer cells. Here, we discuss the evidences supporting 
the amino acids supplementation as a cancer fighting weapon and a possible strategy to counteract the myocyte toxicity associated with 
chemotherapy, possibly by tipping the balance of mTORCs activity. 
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1. INTRODUCTION 
 We know that malnutrition correlates with poor quality of life, 
increased mortality and morbidity and chemotherapy-induced 
toxicity in cancer patients [1, 2]. Conversely, recent studies have 
shown that calorie restriction counteracts the development of cancer 
in experimental models [3] and similar positive results have been 
obtained by introducing specific nutrient supplements and physical 
exercise [4]. Evidences concerning nutrition and altered protein/ 
nitrogen metabolism in cancer have been described since the 50’s 
[5-7] generating the important concept that “the host-tumor 
relationship is the key to the cancer problem” [8]. This would 
suggest a possible link between nutritional habits and cancer 
development [9, 10]. Hence, the main question regarding the host-
cancer relationship can be asked: “nutrients feed best cancer or non-
cancer tissues ?” [11]. 
1.1. Muscle and Visceral Proteins as a Protein/Nitrogen 
Reservoir, which Regulates Global Body Metabolism 
 Until only a few years ago, the muscle was considered a  
tissue which was solely responsible for body movements, but 
understanding the metabolic role of muscle in the body has now 
increased considerably. There is much evidence that the muscle is 
an organ also fundamental to maintain protein and glucose 
metabolism. Indeed, the muscle is the most important reservoir of 
nitrogen as each amino acid contains at least one amino group 
(NH2). Nitrogen is also necessary for pyrimidine and purine 
synthesis which build up nucleic acids and energetic molecules 
such as ATP. Furthermore, nitrogen derived from amino acids is 
essential for producing Nitric Oxide (NO), which is an important 
regulatory molecule for blood circulation, neuro transmission [12] 
and macrophage cytotoxic activity against microbes and tumor 
cells. NO also acts on the muscle, by modulating its structure and  
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function and by stimulating mitochondria biogenesis [13]. The 
importance of the muscle in maintaining global metabolism has 
been confirmed by the fact that many catabolic/anabolic hormone 
receptors are located in this tissue. In addition, the muscle is 
metabolically linked with the liver, kidney, fat tissue and lungs to 
produce metabolic intermediaries fundamental for whole body 
functions.  
 Cancer patients with muscular wasting, sarcopenia and cachexia 
have an altered balance of circulating anabolic (i.e., insulin, insulin-
like growth factors, growth hormones and others) and catabolic 
molecules (i.e., TNF-alpha, cortisol, catecholamines, glucagons and 
cytokines such as interleukins and others) that alter the ratio 
between anabolism and catabolism. This altered ratio might be 
indicated as the “Cancer-related hypercatabolic syndrome, C-RHS” 
that is characterized by significant changes in both the muscular 
and global visceral protein metabolism [14, 15]. Interestingly, the 
continuous turnover of proteins is a process at the root of cell life in 
healthy individuals. For instance, in healthy humans, about 250-
350g of protein are degraded in the muscles every day. Some of the 
amino acids (AAs) produced are reused by the cells for new protein 
synthesis or to produce energy-rich intermediates for oxidation via 
the Krebs cycle and the respiratory chain, but a large quantity of 
AAs are released into the blood to maintain the blood pool of AAs. 
The balance between muscle protein synthesis and breakdown 
determines the overall cell protein/nitrogen content and 
metabolism. The increase of catabolic hormones and/or molecules 
and the reduction of anabolic hormones, in the C-RHS, causes 
muscular proteolysis and AAs release that have various metabolic 
consequences, including insulin resistance, reduced cytoplasmic 
and mitochondrial protein synthesis as well as impaired cell 
function and energy metabolism. The impairment of protein muscle 
and global metabolism in cancer patients has recently been 
demonstrated. Cancer patients have massive muscle proteolysis 
with consequent AA release which causes lean mass muscle loss. 
Indeed, the fundamental role of muscle in whole-body protein 
metabolism has recently been pointed out by Wolfe who wrote that 
“it is imperative the maintenance of muscle mass, strength and 
metabolic function by specific strategy such as physical activity and 
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diet” [16]. Regarding visceral proteins, we have known since the 
seminal studies of Babson and Winnick [17] that tumors 
preferentially use macromolecules, to free amino acids. Albumin is 
the preferred cell source of amino acids as it is the most abundant 
protein in the circulating plasma accounting for about 50-70% of 
human plasma protein reserve. Pinocytosis has been identified as 
the main process used by neoplastic cells to match their nitrogen 
needs. Modulation of the pinosome-lysosome pathway activity is a 
homeostatic mechanism sensitive to the availability of extracellular 
free amino acids, whose role has been found in normal cells, but 
whose potential has not yet been explored in cancer-bearing states. 
Tumor mass has an extremely elevated filtration pressure, several 
times higher than that of kidney mesangial cells, and as a result 
amino acids will pass through the mass at an extremely high speed. 
This would explain why circulating protein metabolism may be 
particularly affected in cancer patients, as tumor cells can nourish 
themselves primarily by pinocytosis of more slowly filtered protein 
macromolecules, which are degraded by lysosomal cathepsin B. In 
normal cells this process is inversely proportional to the availability 
of free amino acids in the plasma. Under these conditions, the liver 
increases consumption of circulating amino acids in an attempt to 
maintain the plasma concentration of albumin constant, with the 
consequence that this “vicious circle” wastes either energy or 
essential amino acids [18, 19]. Nevertheless, we have to consider 
that neoplastic cells consume high amounts of proteins, particularly 
in function of the size of the tumor. For instance, a tumor of 8.8% 
of body weight has a daily nitrogen balance equivalent to 150% of 
the daily retention obtained from the diet [20]. Cancer treatment 
with nutritional support is not yet well established as a clinical 
practice and dedicated guidelines are not yet available. However, 
malnutrition treatment, including nutritional supplementation and 
physical exercise, should be started as early as possible in cancer 
patients. Several studies indicate that selected nutrients, such as 
amino acids, are not simply a caloric supply, but may interfere with 
different mechanisms implicated in the pathogenesis of cachexia. In 
fact, oral ingestion of essential amino acids elicits important 
physiological responses and favorable changes in the balance 
between anabolic and catabolic hormones. It has been shown that 
this balance is significantly modified by both acute or chronic 
ingestion of amino acids [21, 22]. Moreover, there is growing 
evidence that amino acids influence gene transcription and 
translation, so, by directly modulating the effects of hormones and 
energy availability, the amino acids can potentially control protein 
wasting and cachexia [23].  
 AAs in the diet are absorbed after protein digestion by 
pancreatic enzymes. However, the pancreas uses large amounts of 
AAs and energy to produce digestive enzymes [15]. In cancer 
patients, the efficiency of the pancreas and mesenteric circulation 
may be progressively reduced. These conditions can lead to 
impaired AA digestion and absorption and consequently, to reduced 
AA content in the plasma that may be insufficient to maintain 
protein synthesis and energy needs [15]. Therefore, increased 
protein- intake with meals does not necessarily increase muscle and 
visceral protein synthesis. On the contrary, individual AAs 
provided through nutritional supplements do not need to be 
digested. They are rapidly absorbed and are therefore immediately 
available in the bloodstream and transported into cells [15]. In 
addition, we know that specific AAs have multiple metabolic roles 
that go beyond their simple role as building blocks for protein 
synthesis. Essential amino acid (EAAs) stimulate protein synthesis 
in both the young and elderly with or without diseases [24]. It has 
been recently demonstrated that specific mixtures of individual 
AAs, including essential ones, calculated according to defined 
stoichiometric ratios between amino acids and nitrogen content, are 
also capable of: 1) meeting energy needs, 2) maintaining protein 
syntheses and/or 3) stimulating mitochondrial biogenesis [25, 26]. 
These results may be due to the fact that certain AAs can control 
protein synthesis in myocytes. They do this by activating AMP-
activated protein kinase (AMPK) and the mammalian target of 
rapamycin, mTOR. This activity is anabolic and counteracts the 
catabolic stimulation of hormones, cytokines and specific 
molecules produced by neoplastic cells [27]. An increasing number 
of studies on the positive metabolic role of amino acids in cancer 
have been published [28]. The practical clinical consequence of 
these observations is that calorie and nitrogen needs should be 
calculated separately, as indicated out by Layman, rather than just 
calculating nitrogen needs as a percentage of calories provided by 
the diet [29]. 
 Furthermore it is important to note that physical activity 
improves muscle mass and strength and can be recommended in 
sarcopenic and cachectic patients, together with other therapeutic 
strategies. In particular, aerobic exercise increases both mitochondrial 
activity and number, while resistance exercise improves muscle-
mass and strength by increasing proteins synthesis and fiber size 
and by stimulating the mTOR pathway [30].  
 Thus, nutritional supplementation and physical activity could be 
synergic strategies to improve the protein/nitrogen ratio in cancer 
patients to both maintain body metabolism and to counteract 
chemotherapy induced toxicity in muscles. 
1.2. Amino Acids Supplementation as a Cancer Fighting Weapon 
 Researchers have identified in mammalian target of rapamycin 
(mTOR) the main intracellular mediator of cancer development 
induced by nutrition [31]. mTOR is not only activated by nitrogen 
substrates, provided by digestion of macronutrients, but also by 
various stimuli, such as growth factors and energy stress. For these 
reasons, mTOR is at the center of a complex network that controls 
protein synthesis, cell differentiation, growth and proliferation [31-
33]. However, other evidence suggest that mTOR may also play a 
positive role in cancer patients. It has been demonstrated that 
physical exercise stimulates the mTOR pathway and this is 
correlated with the prevention of certain type of cancers [34-36]. 
mTOR can also increase tolerability of chemotherapy and can 
protect against autophagy (frequently associate with cancer resistance 
to therapy) and improve prognosis [37-39]. It is interesting that, it 
has been recently proposed that physical exercise and nutrients, 
such as amino acids, maintain protein synthesis and anabolism 
because they activate different pathways upstream of mTOR [30]. 
Indeed, specific amino acid mixtures activate the mTOR kinase 
cascade that ultimately results in phosphorylation of the ribosome-
associated S6 kinase. Activation of the S6 kinase permits a high 
level of translation of mRNA species that encode ribosomal proteins, 
activating both amino acids cell entry and protein synthesis [30]. In 
addition, physical exercise acts by avoiding protein disarrangement. 
The balance between synthesis and catabolism of proteins (mainly 
muscular but also visceral) is relevant in maintaining global body-
metabolism and integrity as well as the contractile function of 
myocytes. This can avoid malnutrition and sarcopenia [40], which 
are common negative features of cancer that influence and worsen 
chemotherapy side-effects [41-43]. Furthermore, the maintenance 
of muscle-cell integrity is extremely important in cancer, since 
many patients do not receive adequate chemotherapy due to 
myocyte toxicity. Chemotherapy-induced cardiotoxicity that has 
been reported since the beginning of the use of chemotherapy is one 
example of this [44].  
 The apparent discrepancies between the pro-cancer and anti-
cancer action of mTOR is probably due to the fact that it functions 
through multi-protein complexes. mTOR manages many different 
messages by entering into two different multi-subunit complexes; 
mTORC1, localized on the outer membrane of lysosomes and 
mTORC2, whose function requires to be associated with ribosomes. 
The recent knowledge that mTORCs may act either synergistically, 
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independently or also antagonistically, according to the prevalence 
of signaling pathways is another interesting development.  
 The complexity of TORCs regulation seen from those findings, 
may explain the problems encountered in using rapamycin or 
rapalogues in fighting cancer [45, 46].  
 More in detail, mTOR is a highly conserved serine-threonine 
kinase that belongs to the PIKK (phosphoinositide 3-kinase related 
protein kinase) super-family, which includes several large-sized 
kinase proteins involved in nutrient sensing and DNA repair [47-
49]. mTOR functions as the catalytic subunit of two distinct protein 
kinase complexes, designated as mTORC1 (mTOR complex 1) and 
mTORC2 (mTOR complex 2). Both mTORC1 and mTORC2 
complexes comprehend common subunits, including the mTOR 
catalytic subunit and mLST8 (mammalian lethal with sec-13 
protein 8, also known as GβL), whereas other elements distinguish 
them. In particular, mTORC1 contains Raptor (regulator-associated 
protein of mammalian target of rapamycin) [50] and PRAS40 [51-
53], whereas mTORC2 contains Rictor (rapamycin insensitive 
companion of mTOR), Protor (1 or 2 and acts as a Rictor-binding 
protein) [54] and mSin1 (mammalian stress activated map kinase-
interacting protein 1, also called MAPKAP1) [55-57]. Both 
complexes are negatively regulated by Deptor. On the other hand 
mTORC1 and mTORC2 negatively regulate Deptor expression for 
their activity modulation [58, 59]. Nevertheless, most of the 
literature so far published has concentrated on mTORC1 and for 
this reason it is the best characterized. mTOR is activated by 
different stimuli, such as nutrients, growth factors, energy and 
stress signals, exercise and as a result mTORC1 mediates these 
effects on growth and proliferation. The amount and quality of 
nutrients trigger either energy-consuming anabolic pathways under 
nutrient sufficiency, or alternatively energy-producing catabolic 
pathways under stress conditions or starvation. mTORC1 is in 
general, activated under nutrient-rich conditions and its function is 
blocked under nutrient-limiting conditions, and carefully integrates 
these signals to control many fundamental processes involved in 
cellular metabolism and growth by phosphorylating and therefore 
activating p70S6 kinase. This, in turn, phosphorylates ribosomal S6 
protein, leading to increased protein synthesis. The activated 
mTORC1 also mediates the phosphorylation of eIF4E-binding 
protein 1 (4E-BP1) and promotes the formation of the active protein 
synthesis initiation complex [60]. In addition, glucose availability 
and the fluctuation of energy is sensed by the AMP-activated 
protein kinase (AMPK), which works coordinately with mTORC1 
by shifting the cells to catabolic metabolism [61]. 
 As we have already mentioned, nutrients are crucial signals in 
regulating mTORC1 and in particular, amino acids (AAs) are 
essential for mTORC1 activation. In fact, growth factors and other 
stimuli cannot efficiently activate mTOR when AAs are limited 
[62, 63]. The specific AAs that are required and how they trigger 
their signals to mTOR are at present under study, nevertheless it is 
widely accepted that the essential AA leucine is crucial for mTOR 
signaling [64] and that glutamine is required for extracellular leucine 
to start the signal [65]. However, it is not yet well understood in 
which cell compartment the amino acids should be located or how 
they are sensed. One possibility is that AAs accumulate inside the 
lysosomal lumen (i.e. as the result of protein degradation) and here are 
sensed by a large multisubunit vacuolar H+-adenosine triphosphate 
ATPase (v-ATPase). This macromolecular system, consisting of V1 
and V0 domains, is essential in maintaining the low pH necessary 
for the lysosome to work properly and appears to have a role 
downstream of intracellular amino acids in the initiation or 
propagation of the amino acid-induced signal to mTORC1. In 
particular, it has been shown that V0 and V1 subunits, in presence 
of AAs, are associated with Rag GTPase and Ragulator complex, 
leading to mTORC1 activation [66]. Rag proteins are members of 
the Ras family of GTPases and exist in four variants (RagA-D). A 
Rag dimer, consisting of an A/B subunit bound to a C/D subunit, 
binds mTORC1 in the presence of AAs in the lysosome [67]. In 
particular, AAs promote Rag activation, where Rag A/B is loaded 
with GTP and Rag C/D is loaded with GDP, thus causing the 
recruitment of mTORC1 to the lysosomal membrane through the 
Ragulator complex [68]. The Ragulator complex is a scaffolding 
protein consisting of five subunits, namely p18, p14, MP1, C7orf59 
and HBXIP. Considering that a key event in the amino acid-
dependent activation of mTORC1 is the conversion of Rag A/B 
from a GDP- to a GTP-bound state, the discovery that Ragulator 
has a guanine nucleotide exchange factor (GEF) activity towards 
Rag A/B, could be a crucial step [69] towards fully understanding 
this complex mechanism. After recruiting at the lysosome, 
mTORC1 requires another small GTPase called Rheb [70,71] for its 
activation. Rheb is modulated by the tuberous sclerosis complex 
(TSC1/2), which basically works as a GTPase activating protein. 
Because the TSC complex is normally deactivated by the PI3K 
pathway in presence of growth factors, also through AKT-mediated 
phosphorylation, the full activation of mTORC1 can only be 
achieved in the presence of both amino acids and growth factors 
[72, 73]. Exactly how AAs modulate mTORC1 is now the subject 
of extensive debate and study. There have been many publications 
identifying new factors which are potentially involved in this 
pathway and there are reviews that summarize these findings very 
clearly [74, 75]. Although the hypothesis of mTORC1 activation at 
the lysosomal membrane is currently the most experimentally 
accredited, a very recent in vitro study demonstrates that the 
activity of mTORC1 in Rag-depleted cells is maintained outside the 
lysosomes if the cells are cultured in a complete medium [76]. The 
same authors found that leucine starvation did not alter the punctate 
localization of mTORC1 at the lysosomes, unlike starvation for all 
AAs. However, as yet said, leucine appears to be essential to 
activate mTORC1, independently of its localization.  
 It is therefore clear that regulation of mTORCs by AAs is a 
topic which is continuously developing and the common element of 
all these studies appears to be the stimulating effect of AAs on 
mTORC1. Consistent with the critical role of mTOR in regulating 
cell growth and metabolism, its pathway is frequently activated in 
human cancers [77, 78]. As a result, nutrients and in particular AAs 
could play a crucial role in regulating both physiological and 
pathological conditions. 
 The question we need to ask ourselves, is: do AAs always 
activate only mTORC1, leading to stimulation of cell growth and 
proliferation through anabolism, regardless of their type or molar 
ratio? Some and quite recent studies, we shall look at, have shown 
that the regulation of mTOR function is much more complex and 
articulated than previously thought. 
 Oral supplementation with BCAAs (branched chain AAs, i.e. 
leucine, isoleucine and valine), is epidemiologically associated with 
a lower incidence of hepatocellular carcinoma in cirrhotic patients 
[79]. Other interesting studies in vitro, conducted mainly on cells of 
hepatic origin, tried to provide a mechanism of such action of 
BCAAs. In particular, media containing BCAAs and with an 
appropriate Fischer’s ratio (that is the molar ratio of BCAAs leucine, 
valine, isoleucine to aromatic AAs phenylalanine, tyrosine), seem 
to possess specific activity on hepatoma cell lines, inducing 
premature senescence of cells at risk of neoplastic transformation. 
In particular the p21 CIP1/WAF1 protein level is strongly upregulated 
by DNA damage induced by chemotherapeutic drugs only in the 
presence of BCAAs, while increased p21 protein is suppressed by 
rapamycin. These results would indicate that BCAAs positively 
modulate premature senescence of cells at risk of neoplastic 
transformation by upregulating p21 through the mTORC1 pathway. 
As a result chemotherapeutic drugs treatment combined with 
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BCAAs enhances the execution of premature senescence in cells at 
risk of neoplastic transformation and decreases the incidence of 
hepatocellular carcinoma [80].  
 In another study, BCAAs directly prevent insulin-induced cell 
proliferation of hepatoma cell lines by suppressing the insulin 
signaling pathway. This effect is attributed to an enhanced 
apoptosis by antagonizing the anti-apoptotic function of insulin and 
the molecular mechanisms of how BCAA suppresses insulin/PI3K/ 
Akt pathway is dependent on both mTORC1 and mTORC2 
activities. In particular BCAAs function as suppressors of the 
PI3K/Akt pathway by both inducing a negative feedback loop 
through mTORC1/S6K1 activation and by suppressing mTORC2 
kinase activity towards Akt, although the mechanisms involved 
with mTORC2 suppression by BCAA are only conceivable [81].  
 Nishitani and co-workers looked at hepatocellular carcinoma 
cells expressing the EpCAM marker of cancer stem-cells. In the 
presence of BCAAs with a high Fischer’s ratio, the percentage of 
EpCAM-positive cells was significantly reduced and this effect was 
mimicked by prolonged treatment with rapamycin. Further 
experiments on Raptor and Rictor knockdown cells seem to show a 
prominent role of mTORC2 in reducing tumorigenesis, possibly 
hampered by the activation of mTORC1 and, consequently, of 
p70S6 kinase, through inactivation of Rictor [82]. It has also been 
reported that activation of p70S6 kinase feedback loop inhibits 
Rictor phosphorylation, resulting in the suppression of Rictor 
function [83]. As a result, impaired mTORC2 causes a reduction in 
the phosphorylation of Akt at serine 473, whose phosphorylation is 
significantly correlated with cancer stemness [84, 85]. These 
studies underline the increased interest in mTORC2 for its 
implications in tumorigenesis, however [86], they have also 
stimulated new ideas on the role played by the amino acids, or some 
of them in particular, on the pathological mechanisms that lead to 
cancer or to its prevention. 
 On the other hand, mTORC2 senses extra-cellular growth factor 
stimulation through molecular mechanisms that are still largely 
unclear. It is known that, once activated, it phosphorylates several 
major downstream target proteins including AGC family of kinases, 
such as Akt (also known as	  Protein Kinase B, PKB), SGK (Serum 
and Glucocortioid induced Kinases) and PKC (protein kinase C) 
[87-89]. Furthermore, in a recent paper, mTORC2 was shown to 
respond to amino acids through the PI3K/AKT pathway [90]. The 
authors found that by using different starvation conditions, amino 
acids can selectively activate mTORC1 or mTORC2.  
 It is becoming increasingly clear that the mTORC complexes 1 
and 2 work in a very coordinated and tightly controlled way to 
regulate cell metabolism, growth and ultimately cell fate (survival 
or death). Among the effects mediated by mTORC1, it is now well 
established that, via mTORC1, mTOR negatively regulates 
autophagy in presence of nutrients. Nevertheless, very recently, it 
has been reported that mTOR can also operate independently 
through the mTORC2 complex to promote autophagy [91] when 
amino acids availability is limited. It has also been shown that 
mTOR activity is inhibited at the beginning of the autophagy 
process but when starvation is prolonged mTOR is reactivated 
despite ongoing starvation. Under these conditions the role of 
mTORC1 shifts from repressor to become activator of autophagy 
[92] and the reactivation of mTOR is dependent on amino acids as 
the end products of autolysosomal degradation. 
 Under experimental conditions, fasting for 72 hours decreases 
mTORC1 signaling and this is followed by increased protein 
breakdown and a trend towards reduced protein synthesis. 
However, the observed effects on autophagy were contradictory: 
LC3B-I conversion to LCB3B-II was significantly increased, 
although the expected p62 decrease, indicating increased flux 
towards autophagy, was not recorded as there was a slight but 
constant increase. As a result, the conclusions about short term 
fasting and autophagy control [93] remain elusive. 
 In response to growth factor stimulation, mTORC2 has been 
found to phosphorylate Akt on S473, and the protein Rictor (a 
specific component of mTORC2 and not of mTORC1) has been 
demonstrated to be required for this activity [94]. Although this 
establishes a direct link between mTOR and Akt activity, it also 
shows that the mTOR pathway regulation is more entangled than 
previously thought. The interplay between different degrees of the 
mTORC1 /mTORC2 complexes activation could shift a cell’s fate 
from survival to death and vice-versa. The activation of the 
mTORC1 complex could antagonize activity of mTORC2 complex 
thereby reducing Akt phosphorylation on S473 and its signaling. 
Furthermore, the mTORC1 can negatively regulate mTORC2 
through indirect mechanisms involving a negative feedback loop 
directed to phosphorylation of insulin receptor substrate 1 (IRS1) 
[95] as well as through the phosphorylation of the growth factor 
receptor-bound protein 10 (Grb10), which blocks the PI3K pathway 
[96, 97]. Yu and his co-workers suggest that Grb10 might be a 
tumor suppressor regulated by mTORC1. We can deduce that 
mTORC1 can exert tumor suppressor activities through the 
modulation of intermediate activity. It has also been reported that 
mTORC1 can negatively regulate mTORC2 through direct 
mechanisms mediated by phosphorylation of SIN1 (another specific 
component of mTORC2 and not of mTORC1) [98]. Thus the 
resulting Akt suppression leads both to increased levels of cleaved 
caspase 3 and to apoptotic cell death. This in turn increases 
sensitivity to chemotherapy agents such as etoposide and cisplatin. 
 In our laboratory we have obtained preliminary data indicating 
that specific AAs mixtures can induce colon carcinoma HCT116 
cell death. Indeed in these cells an increased amount of cleaved 
caspase 3, after treatment with AAs, was detected. In our experimental 
setup, the amino acids (for the detailed mixture composition see ref 
[99]) are provided exogenously in elevated quantities. Under these 
conditions the mTORC1 is activated as previously observed [100, 
101]. We hypothesize that as a result of the imbalance between 
Essential AA (EAA) and NonEAA provided to cells by our protocol, 
the mTORC1/2 ratio is altered thus triggering the increased 
cleavage of caspase 3. In the same cell line we also observed a large 
increase of the Bax/Bcl2 ratio after AAs treatment (Fig. 1). This 
further supports the idea that AAs, rather than acting by activating 
protein synthesis, can promote apoptosis of cancer cells, at least  
in vitro, through mechanisms that need to be further clarified.  
 Although mTORC1 is the acquired sensor activated by amino 
acids [102], a recent work reports that TORC2 can also be activated 
by amino acids [90]. In light of the complex machinery illustrated 
in the Fig. 2, we believe that amino acids induce and maintain the 
negative loops upstream of mTORC1 and TORC2 so that their 
function is strictly regulated. A further mechanism of mTORCs 
activity control involves the protein Deptor. This is an endogenous 
inhibitor of mTORC1 and mTORC2 but when it is expressed at 
high levels the activity on mTORC2 flips from inhibitor to activator 
possibly by reactivating the PI3K/mTORC2/Akt signaling [58,59]. 
The preferential inhibitory activity of Deptor versus mTORC1 
could represent a valuable tool to be leveraged in order to achieve 
cancer cell growth inhibition and possibly cancer cell death and, at 
the same time, leaving the healthy cells undamaged. We 
hypothesize that the amino acids could also act on this mechanism 
of mTORCs regulation in order to maintain homeostasis of healthy 
cells and to promote cancer cell death. However, the main question 
remains whether amino acids per se, or unbalancing the ratio of 
certain types of amino acids over others, are relevant in promoting 
any advantages or disadvantages in the epigenetic regulation of cell 
health. Current study in our laboratory hopes to answer this 
important question. 
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2.1. Chemotherapy Induced Toxicity: Doxorubicin effects and 
Prevention of Myocyte Toxicity by Essential Amino Acids 
 Anthracyclines are a class of widely used and effective anti-
cancer drugs [103] essential for the treatment of acute leukemia, 
Hodgkin’s and non-Hodgkin’s lymphoma and breast cancer. 
Among these anthracyclines, Doxorubicin (Doxo) is the most 
widely prescribed and effective cytotoxic drug presently used in 
oncology. Unfortunately, the clinical utility of conventional 
anthracyclines is limited by their high toxicity and in particular by a 
dose and time dependent progressive induction of congestive heart 
failure (CHF) [104, 105]. An example, is a study of a cohort of 607 
children treated with anthracyclines, showing that patients treated 
with a cumulative dose of anthracyclines higher than 300 mg/m(2) 
were at high risk of CHF and 15 years after treatment, up to 5% of 
the patients develop anthracycline-induced CHF. The estimated risk 
of CHF increased with time after the beginning of anthracycline 
chemotherapy [106, 107]. This evidence reinforces the need for 
strategies for early detection of chemotherapy-induced CHF and to 
evaluate other chemotherapeutic strategies or cardio-protective 
agents in order to achieve better survival rates.  
2.2. Mechanisms of Anthracyclines/Doxo Toxicity 
a) Toxicity in Cancer Cells 
 The mechanisms of action of anthracyclines in tumor cells 
remain vague. However several mechanisms have been proposed 
including: generation of free radical and reactive oxygen species 
(ROS), leading to DNA damage or lipid peroxidation; DNA 
intercalation, leading to inhibition of macromolecules synthesis; 
DNA binding and alkylation; DNA cross-linking and interference 
with its replication. The hypothesis that ROS may be mediators of 
tumor cell death induced by anthracyclines has been questioned by 
studies in which treatment with ROS scavenger failed to reduce 
Doxo toxicity in tumor cells [reviewed in 108]. As a result, ROS 
production does not seem to be the major cause of tumor cell death 
induced by anthracyclines.  
 The Doxo’s main cellular target is the topoisomerase-II (Top2) 
[109]. Doxo binds both DNA and Top2 to form the ternary Top2-
Doxo-DNA cleavage complex, which triggers cell death. There are 
two Top2 enzymes: Top2α and Top2β. Top2α, is a known marker 
of cell proliferation, being overexpressed in tumors and being  
not detectable in quiescent tissues. Therefore, Top2α is thought to 
be the molecular target of Doxo’s anticancer activity [110, 111]. 
Adult mammalian cardiomyocytes express Top2β but no detectable 
Top2α. Top2β is also a target for doxorubicin, and the Top2β-
doxorubicin-DNA ternary cleavage complex can induce DNA 
double-strand breaks leading to cell death. Cardiomyocyte-specific 
deletion of Top2β protects mice from the development of Doxo-
induced progressive heart failure, suggesting that Doxo-induced 
cardiotoxicity is mediated by Top2β in cardiomyocytes [110]. 
b) Toxicity in Healthy Muscle/Heart Cells 
 Although it is still not yet fully clear, the mechanism 
responsible for Doxo-induced muscle and cardio-toxicity seems to 
Fig. (1). Preliminary data indicating that specific amino acid mixtures can induce colon carcinoma HCT116 cell death. It is evidenced as an increased amount 
of cleaved caspase 3 and a large increase of the Bax/Bcl2 ratio. 
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be very different from that involved in antitumor activity. Doxo 
reduces the expression of a variety of muscle-specific proteins, 
including contractile proteins, sarcoplasmic reticulum proteins and 
mitochondrial proteins. Loss in muscle myofibrillar proteins is 
associated with reduced contractility and may explain the pathologic 
features of Doxo-induced cardiomyopathy. The damaging effects of  
Doxo change the morphology of the cardiomyocytes that manifest 
themselves as dilation of heart chambers, fibrosis, vacuolization, 
reduced myofibrils, mitochondrial disruption and chromatin 
disorganization [108]. The main cardiomyocyte organelles damaged 
by Doxo are the mitochondria, where the drug accumulates [112, 
113]. Many mechanisms for Doxo-induced cell injury have been 
proposed [110, 114, 115]. One major hypothesis is that oxidative 
stress is generated through interaction with iron and oxygen. 
Administering Doxo to laboratory animals [116-118] and humans 
[119-122] increased plasma and tissue ROS and lipid peroxidation 
 
Fig. (2). Interplay between mTORC1 and mTORC2 in mediating the molecular effects of amino acids (please refer to the text for explanation). 
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products but decreased plasma and tissue anti-oxidant levels. Most 
studies support the view that Anthracyclines/Doxo increase ROS 
and lipids peroxidation by interacting with mitochondrial enzymes, 
therefore inhibiting nucleic acid, protein synthesis and 
mitochondrial function [108, 123, 124]. It seems that ROS also play 
a key role in the pathogenesis of Doxo induced cardiomyopathy. 
The heart is particularly susceptible to Doxo-induced oxidative 
damage because of the large density/volume of mitochondria. These 
are both important sources and targets of ROS, given their high rate 
of oxygen consumption and lower antioxidant defenses in the heart 
compared with other organs, such as the liver [125, 126]. Many 
intracellular enzymes can mediate Doxo effects. These include, the 
microsomal nicotinamide adenine dinucleotide phosphate (NADPH)-
cytochrome P450 reductase, which is a primary site for ROS generation 
from a chemically diverse group of compounds including many 
anti-neoplastic agents. NADPH-dependent microsomal enzymes are 
present in all tissues. In cardiac cells, however, due to a mitochondrial 
nicotinamide adenine dinucleotide (NADH) dehydrogenase that is 
not present in other types of cells, this enzyme generates very high 
levels of free radicals in the presence of doxorubicin. This may 
explain the high degree of oxidative stress that the drug causes in 
cardiac mitochondria. Therefore, the specific structure of the 
electron transport system of cardiac mitochondria is responsible for 
the high level of oxidative stress generated by Doxo and for the 
development of cardiomyopathy [127].  
2.3. Prevention of Anthracycline/Doxo-induced Toxicity 
 At present, there is no specific treatment for Anthracyclines/ 
Doxo induced cardiomyopathy. Doxo-induced cardiomyopathy is 
refractory to conventional therapy [128], although β-blockers and 
angiotensin-converting enzyme (ACE) inhibitors may be useful  
in patients with congestive heart failure [129, 130]. Cardiac 
transplantation remains the last option for patients with end-stage 
heart failure due to Doxo cardiomyopathy [130, 131-133].  
 The first line of defense against cardiotoxicity remains, whenever 
possible, the containment of the cumulative dose below 450 mg/m2. 
For this purpose, numerous therapeutic strategies have been 
proposed (using Doxo analogues, antioxidants, iron chelators, etc.) 
[108] but none has been particularly successful. However, the 
administration of antioxidants has proved to be effective to prevent 
damage in acute Doxo intoxication. Recent evidence has shown that 
carotenoids (50 and 100 µg/kg) could prevent the acute cardiotoxicity 
and hepatotoxicity induced by Doxo (25 mg/kg i.p.) in tumor bearing 
mice [134]. Presently, dexrazoxane is the sole clinically approved 
cardioprotective agent against anthracycline-induced cardiotoxicity. 
Its activity has been attributed to the iron-chelating effects of its 
metabolite which protect against oxidative stress. However, 
dexrazoxane is also a catalytic inhibitor of Top2 and recent findings 
show that dexrazoxane may protect cardiomyocytes via its catalytic 
Top2 inhibitory activity rather than iron-chelation activity [111]. 
 Recently, researchers have focused on the development of 
liposomal anthracyclines to mitigate the life threatening effects of 
conventional anthracyclines. In particular, pegylated liposomal 
Doxo (PLD), has proven to be an effective anti-tumor drug for 
metastatic breast and ovarian cancer, with less toxicity than 
conventional anthracycline [135-137]. The PLD is a unique form of 
Doxo packed in a liposome coated with polyethylene glycol. This 
modification prevents plasma protein adsorption to the liposome 
surface and shows that PLDs can remain in the circulation much 
longer than non-PLD. Due to its increased permeability and 
retention effect, liposomes deliver drugs more specifically to cancer 
tissues, and limit the exposure of healthy cells to the drug thus 
reducing toxicity [136]. 
 Experimental and clinical studies suggest that anthracycline/ 
Doxo-induced cardiotoxicity can also be prevented by administering 
Coenzyme-Q10 (Co-Q10) before and during cancer chemotherapy, 
without interfering with the antineoplastic action of the drugs. Co-
Q10 is an essential component of the electron transport system and 
is probably the most important antioxidant in cardiac myocytes, 
where it has a protective effect against oxidative damage to 
mitochondrial proteins and mtDNA. Co-Q10 may prevent the 
anthracycline from being reduced to its semiquinone by the 
cytosolic NADH dehydrogenase activity. This is possibly due to 
competition for the enzyme active site. Co-Q10 administration 
seems to prevent damage to the cardiomyocytes mitochondria, thus, 
preventing the development of drug-induced cardiomyopathy [127].  
 Unfortunately, so far, the promising results obtained through 
antioxidants administration as protection against Doxo-induced 
cardiotoxicity were obtained in animal models and rarely translated 
into a similar protection in humans. The fact that Doxo cardiotoxicity 
may remain silent for decades has not motivated the physicians into 
prescribing drugs to counteract the possible Doxo injuries if these 
are not evident. 
2.4. Physical Activity as a Possible Alternative Strategy for 
Prevention of Anthracycline/Doxo-induced Toxicity 
 Indeed, a non-pharmacological approach to prevent cardiac and 
muscle damage induced by Doxo is based on physical exercise and 
calorie restriction. Regular exercise improves metabolism and 
especially mitochondrial capacity in the hearts of former Doxo 
patients. A study showed that low-intensity aerobic exercise, 
concomitant with low-dose Doxo administration (cumulative dose 
of 4mg/kg) would mitigate the Doxo-induced cardiotoxicity while 
also improving the therapeutic efficacy of Doxo in a murine model 
of melanoma [138]. Exercise training protects against Doxo-
induced myopathy in both heart and skeletal muscles, by reducing 
FoxO1 and FoxO3 expression, and the transcription of their target 
genes [i.e., atrogin-1/muscle atrophy F-box (MaFbx), muscle ring 
finger-1 (MuRF-1), and BCL2/adenovirus E1B 19 kDa protein-
interacting protein 3 (BNIP3)]. Furthermore, exercise increases 
PGC-1α in both heart and skeletal muscles and the increased PGC-1α 
expression is known to suppress FoxO activity [139] and to regulate 
mitochondrial biogenesis [140].  
2.5. Calorie Restriction may Resemble the Positive effects of 
Exercise in Anthracycline/Doxo-induced Toxicity 
 A combined approach of low-dose caloric restriction (20%) and 
resveratrol was used therapeutically to induce autophagy and to 
provide protection against Doxo-mediated toxicity in the hearts of 
26-months-old rats [141]. The protective role of calorie restriction 
may be due, at least in part, to increased autophagic fluxes in 
cardiac tissue, suggesting the protective role of cardiac autophagy 
in removing damaged cell structures after Doxo treatment [142].  
 Other published data suggest that, in skeletal muscle, ghrelin, a 
potential cancer cachexia fighting agent, suppresses the Doxo-
induced activation of apoptosis and enhances the cellular signaling 
of autophagy. This then exerts protective effects against Doxo-
induced muscle toxicity [143]. Furthermore, ghrelin effectively 
improves cardiomyocyte survival and size maintenance by 
suppressing excessive autophagy through both ROS inhibition and 
mTOR induction by suppressing AMPK activity and by stimulating 
p38-MAPK activity [144].  
2.6. Oral Supplementation of Special Mixture of Aminoacids 
Maintains the Integrity and Function of the Muscle 
 Recent data show that oral supplementation of special mixture 
of aminoacids maintains the integrity and function of the muscle, 
induces mitochondriogenesis, contains ROS production and inhibits 
apoptosis [145]. Furthermore, chronic oral essential amino acids 
(EAA) administered in aged rats significantly increased the 
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expression and activation of mTOR and, possibly, mTOR activated 
metabolic pathways, which may lead to increased protein synthesis 
[145]. Further recent evidences revealed the important antiaging 
role of chronic EAA supplementation in mammals. It increased the 
average life span of mice, by increasing mitochondrial biogenesis 
and sirtuin 1 expression in primary cardiac and skeletal myocytes 
and in cardiac and skeletal muscle, via eNOS- and mTOR-mediated 
mechanisms. This was accompanied by enhanced physical 
endurance. Moreover, the ROS defense genes were upregulated, 
and ROS production was reduced [99]. EAA supplementation was 
also effective in reducing damage caused by alcohol in the liver and 
by rosuvastatin in the kidney [146, 147]. Together, these studies 
offer a rationale for exploring the role of EAA in preventing and 
controlling chemotherapy-induced toxicity.  
 To test this intriguing hypothesis we performed a pilot study 
using an experimental model in which acute cardiomyopathy was 
induced in male mice by a single i.p. injection of Doxo (15 mg/kg) 
[148]. A group of Doxo-treated mice was daily supplemented with 
an EAA mixture (1.5 g/kg) for 14 days. The results (unpublished 
results) confirmed that Doxo has significant negative effects on the 
heart and body-mass of mice, inducing cardiomyocyte alteration 
and greatly impairing the distribution and morphology of 
mitochondria. Conversely, the EAA supplementation preserved 
whole body mass, cardiomyocyte architecture and mitochondrial 
integrity, thus counteracting the Doxo effects on autophagic paths 
(Corsetti’s personal communication).  
 In addition we also studied the possible interference of EAA on 
Doxo toxicity in colon (HCT116), mammary gland (MCF7) and 
melanoma (M14) cancer cell lines in vitro. We observed that Doxo 
promotes cell apoptosis and EAA increase and does not counteract 
Doxo therapeutic efficacy on cancer cells. Unexpectedly, EAA, 
even in absence of Doxo, have a powerful apoptotic effect on 
cancer cells (unpublished results, Flati’s personal communication). 
 These preliminary data, although obtained from experimental 
models of acute intoxication, may open a new non-pharmacological 
path to prevent/contain the onset of anthracycline-induced 
cardiotoxicity.  
 Double blind controlled studies in cancer bearing patients 
undergoing chemotherapy are in progress in different clinical 
research centers. 
CONCLUDING REMARKS 
 Many studies have indicated that the regulation of cell 
homeostasis is very complex and involves many contemporarily 
positive and negative controlling messages, often with highly 
contrasting effects. Drugs may act on one or more cell growth rate 
controlling steps, but in a clinical setting they have often failed to 
fully reach their expectations. In our laboratory, we are exploring 
whether amino acids, (the active metabolites involved in both cell 
energy production and syntheses) may be used to modify, the 
expression and direction of metabolic fluxes and, possibly, drug 
responses.  
 Modulating mTOR, and its active complexes mTORC1 and 2 
intertwined regulation, in different physiological environments and 
thus managing to modulate the prevalence of one or another mTOR 
complex activity, could be an important step towards achieving 
better cancer therapies. This strategy is thought to protect healthy 
cells from toxicity - as preliminary data have shown in mouse 
muscles and hearts - while amplifying therapeutic response in 
diseased animals.  
 Most probably, altering the essential to non-essential amino 
acid ratios is a means 1) to achieve physiologically protective goals 
and also 2) to unveil the pathways that underline the cancer cells 
peculiar efficiency in surviving to chemotherapy, 3) in ruling 
substrates availability and 4) controlling mTOR functional 
messages (survival or death). 
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